Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 19/20 | 0.56 |
| ▸ | ADORA2B | P29275 | 18/20 | 0.56 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20400552 | 0.92 | ADORA2A (0.57) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20400587 | 0.87 | ADORA2A (0.58) | ADORA2AADORA2BADORA1 | |
| SCHEMBL30401959 | 0.85 | ADORA2A (0.53) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20416599 | 0.85 | ADORA2A (0.53) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20401347 | 0.82 | ADORA2A (0.50) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20401358 | 0.82 | ADORA2A (0.54) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20401149 | 0.79 | ADORA2A (0.48) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20401323 | 0.79 | ADORA2A (0.64) | ADORA2AADORA2BADORA1 | |
| SCHEMBL20401320 | 0.79 | ADORA2A (0.64) | ADORA2AADORA2BADORA1 | |
| SCHEMBL30401435 | 0.79 | ADORA2A (0.64) | ADORA2AADORA2BADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2018136700-A1 | AZOLOPYRIMIDINE FOR THE TREATMENT OF CANCER-RELATED DISORDERS | ARCUS BIOSCIENCES, INC. (US) | 2018-07-26 | — | — | WO | disclosed |
| US-20160058875-A1 | TREATMENT OF CANCER | CERULEAN PHARMA INC. (US) | 2016-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160058875-A1 | TREATMENT OF CANCER | TOP1, TOP2A, TOP2B | ADORA2A 2680/4885ADORA2B 3571/4885ADORA1 3367/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.